ArticleACS nano2017
Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.
Abstract read
In one paragraph
Article in ACS nano, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy.Frontiers in immunology · 2022Pooled it
- Evaluation of methods to increase the expression of cytokine-induced killer cell chemoattractant cytokines in pancreatic cancer.Gene therapy · 2026Article
- Small molecules targeting the PD-1/PD-L1 axis for cancer immunotherapy.Theranostics · 2026Review
- Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities.Drug delivery and translational research · 2025Review
- Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies.Discover oncology · 2025Review
- Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025Review
- Novel insight and perspectives of nanoparticle-mediated gene delivery and immune-modulating therapies for pancreatic cancer.Journal of nanobiotechnology · 2024Review
- Endoplasmic reticulum-targeted delivery of celastrol and PD-L1 siRNA for reinforcing immunogenic cell death and potentiating cancer immunotherapy.Acta pharmaceutica Sinica. B · 2024Article
- Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma.Pharmaceutical research · 2024Article
- Extracellular vesicles hybrid plasmid-loaded lipid nanovesicles for synergistic cancer immunotherapy.Materials today. Bio · 2023Article
- Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy.Journal of nanobiotechnology · 2023Review
- Nanocarriers for cancer nano-immunotherapy.Drug delivery and translational research · 2023Review
- A Three-in-One Nanoscale Coordination Polymer for Potent Chemo-Immunotherapy.Small methods · 2023Article
- Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets.Frontiers in oncology · 2023Review
- A new approach to overcoming resistance to immunotherapy: nanotechnology.Frontiers in oncology · 2023Review
- Regulation of pancreatic cancer therapy resistance by chemokines.Seminars in cancer biology · 2022Review
- Microfluidic affinity selection of active SARS-CoV-2 virus particles.Science advances · 2022Article
- Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy.Pharmaceutics · 2022Review
- Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Lei MiaoDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, ‡Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, §Carolina Center for Genome Sciences, and ∥UNC & NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Jingjing LiDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, ‡Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, §Carolina Center for Genome Sciences, and ∥UNC & NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Qi LiuDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, ‡Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, §Carolina Center for Genome Sciences, and ∥UNC & NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Richard FengDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, ‡Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, §Carolina Center for Genome Sciences, and ∥UNC & NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Manisit DasDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, ‡Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, §Carolina Center for Genome Sciences, and ∥UNC & NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
C Michael LinDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, ‡Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, §Carolina Center for Genome Sciences, and ∥UNC & NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Tyler J GoodwinDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, ‡Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, §Carolina Center for Genome Sciences, and ∥UNC & NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Oleksandra DoroshevaDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, ‡Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, §Carolina Center for Genome Sciences, and ∥UNC & NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Rihe LiuDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, ‡Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, §Carolina Center for Genome Sciences, and ∥UNC & NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.
Leaf HuangDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, ‡Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, §Carolina Center for Genome Sciences, and ∥UNC & NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-9421-8283
University of North Carolina at Chapel Hill · US
Funding
Translational Nanosystems for Improved Lung Cancer Treatment with Small MoleculesU54CA151652 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAROON, ZISHAN A, TEPPER, JOEL E · 2010 to 2014
$12.1MSmall Animal Imaging CoreU54CA198999 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO · 2015 to 2019
$11.9MHepatic Non-viral Gene TherapyR01DK100664 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUANG, LEAF · 2013 to 2017
$1.7MNanocrystals for the Treatment of Multidrug Resistance in CancerR01CA149387 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUANG, LEAF · 2011 to 2015
$1.5MNovel Single Domain Antibodies with Multivalency and MultispecificityR01CA157738 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, RIHE · 2012 to 2016
$1.5MNCI NIH HHS R01 CA149387NCI NIH HHS R01 CA157738NCI NIH HHS U54 CA151652NCI NIH HHS U54 CA198999NIDDK NIH HHS R01 DK100664
Abstract
Pancreatic tumors are known to be resistant to immunotherapy due to the extensive immune suppressive tumor microenvironment (TME). We hypothesized that CXCL12 and PD-L1 are two key molecules controlling the immunosuppressive TME. Fusion proteins, called traps, designed to bind with these two molecules with high affinity (K
Indexed as
AnimalsB7-H1 AntigenCarcinoma, Pancreatic DuctalChemokine CXCL12DNAGenetic TherapyImmunotherapyMiceMice, Inbred C57BLT-LymphocytesTumor EscapeTumor MicroenvironmentB7-H1 AntigenChemokine CXCL12DNAallograft modelCXCL12pancreatic ductal adenocarcinomaPD-L1trap protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.